Pixium Vision announced the first successful implantation and activation of IRIS II in the UK. This epiretinal implant with 150 electrodes is intended for patients who have lost sight as a result of retinitis pigmentosa (RP).
The first implant of IRIS II in UK was successfully performed in September, by Mahi Muqit, PhD, FRCOphth, Consultant Ophthalmologist and Vitreoretinal Surgeon at Moorfields Eye Hospital, study Principal Investigator in UK. This is part of Pixium Vision’s ongoing multicenter clinical trial to assess the performance of IRIS II as a treatment to compensate for blindness by the intended provision of a form of bionic vision and greater autonomy for patients. Moorfields Eye Hospital NHS Foundation Trust is one of the clinical centers of excellence participating in the multicenter European study across France, Germany and Austria, UK and Spain.
“This first IRIS II retinal implant in the UK was successfully completed for the 73 year old retinitis pigmentosa patient. The 150 electrode implant with its explantable design, may become an innovative option for the retinal surgeons. Participation in this European clinical trial allows us to evaluate the new system,” Dr. Muqit said in a company news release. “The patient’s system was activated and he reported first perception of light. Per clinical protocol, the patient will now enter training and readaptation to learn how to interpret the new light signals.”
The implant activation and first light perception illustrates that some visual perception may become available. It precedes the normal readaptation and re-education process where, per protocol, the patient enters a learning process to interpret the new form of bionic vision which is different to the natural form of vision.
"The first IRIS II implant in UK at the prestigious Moorfields hospital is part of the company’s strategy to continue to expand its presence across centers of excellence in Europe. Pixium Vision is dedicated to conceive, develop and bring meaningful bionic vision innovations to surgeons, which shall enable them to treat patients who have lost sight to retinal dystrophies," Khalid Ishaque, CEO of Pixium, said in the news release.
In parallel, the company continues to progress with development of its second system, PRIMA, a wireless subretinal implant, with a less invasive design than IRIS and which is intended to be suitable, particularly, for AMD. First preclinical studies enabled the submission to regulatory bodies for a feasibility study for age-related macular degeneration (AMD).